Small Business Resources, Business Advice and Forms from AllBusiness.com

Zentaris key to biotech outlook.

WHEN Zentaris, the oncology research and development arm of Germany's specialty chemicals firm Degussa, lists in Frankfurt this month, fellow biotechnology companies will be watching closely to see whether investor appetite is starting to return to the sector.

The float, if successful, will be one of Europe's largest bio-tech offerings and is being seen as a key indicator of investor sentiment towards the sector. For, while their technology counterparts continue to struggle to regain investor interest, recent events show that money is, in fact, beginning to flow back in

In addition, make sure to read these premium articles also available with your free trial:

T T T
art_print Printart_email Email 16x16-digg-guy  Digg It delicious-small  del.icio.us

Related Resources

Free AllBusiness Articles

  • Betting on biotech--Industry grows healthy in NJ
    • New Jersey is, without a doubt, emerging as a leader in the biotech industry. "We're bullish on biotech in New Jersey. We have great potential to be a leader and to grow and attract the best," says Debbie Hart, president of the Biotechnology Council of New Jersey, Trenton, an active ......
  • Strategic applications of technology adoption life cycle in biotechnology industry.
    • ABSTRACT The adoption of biotech products in the healthcare industry conforms and varies from the traditional technology adoption life cycle model created by Rogers and his contemporaries. The Innovator and Early Adopter stages are effectively eliminated by the biotech product approval process, i.e., the patent process, clinical testing, and the ......
  • India.
    • India: Consisting of approximately 800 companies, India's biotech industry is estimated to be worth $6.7 billion by 2010, with sales of human and animal health care products totaling $200 million by 2005. Human health applications currently account for 60% of the market, while industrial applications (including genomics and bioinformatics) account ......
  • Array BioPharma Achieves Milestone for Dosing MEK Inhibitor, ARRY-704, in Phase 1 Clinical Trial.
    • Array Receives $2,000,000 Milestone Payment from AstraZeneca BOULDER, Colo. -- AstraZeneca PLC dosed its first cancer patient in a Phase 1 clinical trial with our MEK inhibitor, ARRY-704 (AZD8330), triggering a $2 million milestone payment from AstraZeneca to Array BioPharma Inc. (NASDAQ: ARRY). In December 2003, Array partnered the oncology ......
  • Biotech, Life Sciences Thriving in NJ with Strong State Support
    • By all measurements, biotechnology and the life sciences are thriving in New Jersey. With the strong support of state government, research universities and a host of prominent trade groups like the Biotechnology Council of New Jersey, the HealthCare Institute of New Jersey, the New Jersey Technology Council and the Research ......
  • BioVeris completes merger with Roche.
    • BioVeris Corporation's (Gaithersburg, MD) stockholders voted to approve Roche's (Basel, Switzerland) acquisition of BioVeris. The acquisition will allow Roche Diagnostics to expand its immunochemistry business from the human diagnostic field into new market segments such as life science research, life science development, patient self testing, veterinary testing, drug discovery, ......
  • Industry. (Personals/Personnalites).
    • SemBioSys Genetics Inc., a Calgary-based biotechnology company, announced in June that its scientific founder and chief scientific officer, Maurice Moloney, has been appointed to a three-year term on the Natural Sciences and Engineering Research Council of Canada (NSERC). Moloney has been involved with NSERC since 1987, serving on the Strategic ......

Video

Forms

Blogs

  • Venture Capital Bill Rockets Out of Committee
    • The House Small Business Committee has quickly approved a bill to let firms owned by venture capital companies participate in federal small business programs, much to the dismay of SMB advocates.
  • As Federal R&D Funding Fades, State Efforts Ramp Up
    • The federal government is leaving the nation and small businesses another sad legacy that may be felt for years to come: Spending on research and development has been declining for most of President Bush's term in office.
  • 20 plans join to offer online eligibility verification
    • CAQH - the Council for Affordable Healthcare - announced today that more than 20 leading healthcare organizations have committed to making it significantly easier for physicians and other health professionals to verify patient insurance information . IBy March 31, 2007, these organizations will electronically exchange eligibility and benefits information with ......
  • Budget Cuts, Mismanagement Muddle SBIR Grants
    • The government's Small Business Innovation Research program has funded important research. But budget cuts and mismanagement have taken their toll on the program.
  • All Bloggers
Related Topics
Tools

Sponsored Links

Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy

Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Article Archives
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.